Revelation Biosciences (OTCMKTS:REVB) Upgraded at Zacks Investment Research

Revelation Biosciences (OTCMKTS:REVBGet Rating) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report released on Saturday, Zacks.com reports. The brokerage presently has a $0.75 price objective on the stock. Zacks Investment Research‘s price objective would suggest a potential upside of 32.28% from the stock’s previous close.

According to Zacks, “Revelation Biosciences Inc. is a clinical-stage life sciences company. It focused on the development of immunologic-based therapies for the prevention and treatment of disease. The company’s product pipeline includes REVTx-99, REVTx-200 and REVDx-501. Revelation Biosciences Inc., formerly known as Petra Acquisition Inc., is based in NEW YORK. “

Separately, Roth Capital started coverage on Revelation Biosciences in a research report on Thursday, February 17th. They issued a “buy” rating and a $12.00 price target for the company.

OTCMKTS REVB opened at $0.57 on Friday. The business’s fifty day moving average is $1.14 and its 200 day moving average is $8.92. Revelation Biosciences has a fifty-two week low of $0.55 and a fifty-two week high of $11.29.

Revelation Biosciences (OTCMKTS:REVBGet Rating) last issued its earnings results on Monday, May 16th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.25). On average, equities research analysts anticipate that Revelation Biosciences will post -0.57 EPS for the current year.

In related news, Director George F. Tidmarsh purchased 20,000 shares of the company’s stock in a transaction that occurred on Friday, February 25th. The stock was bought at an average price of $1.60 per share, for a total transaction of $32,000.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 19.90% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in REVB. Ergoteles LLC bought a new position in Revelation Biosciences in the first quarter worth approximately $25,000. Marshall Wace LLP bought a new position in Revelation Biosciences in the fourth quarter worth approximately $508,000. Finally, Monashee Investment Management LLC acquired a new position in shares of Revelation Biosciences during the first quarter worth $932,000. Hedge funds and other institutional investors own 73.36% of the company’s stock.

Revelation Biosciences Company Profile (Get Rating)

Revelation Biosciences, Inc, a clinical -stage biopharmaceutical company, focuses on the development or commercialization of innate immune system therapeutics and diagnostics. The company's lead therapeutic candidate is REVTx-99, an anti -viral nasal drop for the prevention or treatment of respiratory viral infections, as well as for the prevention or treatment of nasal congestion due to allergies or chronic rhinosinusitis.

Further Reading

Get a free copy of the Zacks research report on Revelation Biosciences (REVB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Revelation Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revelation Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.